Trial Profile
A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- 11 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Sep 2008 New trial record.